These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 11742881)

  • 1. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice.
    Davis HR; Compton DS; Hoos L; Tetzloff G
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2032-8. PubMed ID: 11742881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice.
    Braun A; Yesilaltay A; Acton S; Broschat KO; Krul ES; Napawan N; Stagliano N; Krieger M
    Atherosclerosis; 2008 May; 198(1):77-84. PubMed ID: 18054357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice.
    Liu J; Lu H; Howatt DA; Balakrishnan A; Moorleghen JJ; Sorci-Thomas M; Cassis LA; Daugherty A
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1826-34. PubMed ID: 26044581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe.
    Dietrich T; Hucko T; Bourayou R; Jahnke C; Paetsch I; Atrott K; Stawowy P; Gräfe M; Klein C; Schnackenburg B; Fleck E; Graf K
    Int J Cardiovasc Imaging; 2009 Dec; 25(8):827-36. PubMed ID: 19662512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice.
    Davis HR; Hoos LM; Tetzloff G; Maguire M; Zhu LJ; Graziano MP; Altmann SW
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):841-9. PubMed ID: 17218600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular protective effects of ezetimibe in ApoE-deficient mice.
    Nakagami H; Osako MK; Takami Y; Hanayama R; Koriyama H; Mori M; Hayashi H; Shimizu H; Morishita R
    Atherosclerosis; 2009 Mar; 203(1):51-8. PubMed ID: 18603252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplementation with curcumin inhibits intestinal cholesterol absorption and prevents atherosclerosis in high-fat diet-fed apolipoprotein E knockout mice.
    Zou J; Zhang S; Li P; Zheng X; Feng D
    Nutr Res; 2018 Aug; 56():32-40. PubMed ID: 30055772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Antiatherogenic Properties of Ezetimibe Using
    Dumas LS; Briand F; Clerc R; Brousseau E; Montemagno C; Ahmadi M; Bacot S; Soubies A; Perret P; Riou LM; Devoogdt N; Lahoutte T; Barone-Rochette G; Fagret D; Ghezzi C; Sulpice T; Broisat A
    J Nucl Med; 2017 Jul; 58(7):1088-1093. PubMed ID: 28280218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice.
    Kuhlencordt PJ; Padmapriya P; Rützel S; Schödel J; Hu K; Schäfer A; Huang PL; Ertl G; Bauersachs J
    Atherosclerosis; 2009 Jan; 202(1):48-57. PubMed ID: 18479686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis.
    Huff MW
    Can J Clin Pharmacol; 2003; 10 Suppl A():26A-32A. PubMed ID: 14571303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.
    Sandoval JC; Nakagawa-Toyama Y; Masuda D; Tochino Y; Nakaoka H; Kawase R; Yuasa-Kawase M; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Ohama T; Matsuyama A; Nishida M; Ishigami M; Komuro I; Yamashita S
    J Atheroscler Thromb; 2010 Sep; 17(9):914-24. PubMed ID: 20543519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.
    Zhang SH; Reddick RL; Avdievich E; Surles LK; Jones RG; Reynolds JB; Quarfordt SH; Maeda N
    J Clin Invest; 1997 Jun; 99(12):2858-66. PubMed ID: 9185508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action.
    Moghadasian MH; McManus BM; Godin DV; Rodrigues B; Frohlich JJ
    Circulation; 1999 Apr; 99(13):1733-9. PubMed ID: 10190884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet.
    Stepankova R; Tonar Z; Bartova J; Nedorost L; Rossman P; Poledne R; Schwarzer M; Tlaskalova-Hogenova H
    J Atheroscler Thromb; 2010 Aug; 17(8):796-804. PubMed ID: 20379054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
    Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ezetimibe on atherosclerosis in preclinical models.
    Davis HR; Lowe RS; Neff DR
    Atherosclerosis; 2011 Apr; 215(2):266-78. PubMed ID: 21397230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice.
    Koulis C; Chen YC; Hausding C; Ahrens I; Kyaw TS; Tay C; Allen T; Jandeleit-Dahm K; Sweet MJ; Akira S; Bobik A; Peter K; Agrotis A
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):516-25. PubMed ID: 24436372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461.
    Salisbury BG; Davis HR; Burrier RE; Burnett DA; Bowkow G; Caplen MA; Clemmons AL; Compton DS; Hoos LM; McGregor DG
    Atherosclerosis; 1995 May; 115(1):45-63. PubMed ID: 7669087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
    Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
    Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.